Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/pibrentasvir for 6 weeks in acute hepatitis C virus infection: pilot study
2017-002221-37Phase 3Terminated
- Sponsor
- Policlinico Paolo Giaccone
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of glecaprevir + pibrentasvir in acute hepatitis C (HCV) and hepatitis C virus infection, sponsored by Policlinico Paolo Giaccone. Primary endpoint: SVR12. Started Nov 2020; status: terminated.
02
Drugs
glecaprevir + pibrentasvir
03
Conditions
acute hepatitis C (HCV)hepatitis C virus infection
Beyond the preview
Go deeper on 2017-002221-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002221-37.